AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Metformin 500 mg b.i.d.
Description: Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.
Description: MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Metformin 1000 mg b.i.d.
Description: Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Study NCT00103857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Metformin 1000 mg b.i.d.
Description: Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Study NCT00636168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Study NCT00636168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Study NCT01622023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-uterine insemination
Description: Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
Study NCT01622023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-uterine insemination
Description: Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
Study NCT04309578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Capecitabine and Cisplatin
Description: * Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1
Study NCT04109651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing intervention
Description: Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants.
Study NCT04109651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Description: Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants.
Study NCT00186121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex)
Description: Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
Study NCT01998854 — intervention group
Intervention type: DEVICE
Intervention: VizAblate System
Description: The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
Study NCT04247724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational handball
Study NCT04247724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Study NCT03088813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: IV
Study NCT01545427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 200 mg bid for 6 months
Study NCT01545427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo coated to match appearance of Gleevec identically.
Study NCT00168454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A injected into detrusor on Day 1
Study NCT00168454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) injected into detrusor on Day 1
Study NCT02081599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teneli (Teneligliptin)
Study NCT02081599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneli (Teneligliptin)
Study NCT02081599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02081599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Study NCT02081599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT01103063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus chloroquine
Description: combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
Study NCT01103063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCV 3DAA FDC
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-791325
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Study NCT02045693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Study NCT01041287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is >125/80 for the remaining 8 weeks
Study NCT01041287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is >125/80 for the remaining 8 weeks
Study NCT02446080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk drink with probiotic culture
Description: The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
Study NCT02446080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk drink
Description: The control group was asked to drink 150 ml per day of dairy drinks.
Study NCT04253587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabyrinthVR
Description: Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
Study NCT04253587 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Games
Description: Commercially-available, narrative computer games marketed as cognitively enriching.
Study NCT04253587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coherence
Description: Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
Study NCT04253587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet
Description: Tablet computer playing Labyrinth VR game but in 2.5D
Study NCT02979223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid
Description: sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group
Study NCT02979223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid
Description: sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group
Study NCT03626545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
Study NCT03626545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
Study NCT03626545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
Study NCT03626545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
Study NCT03057080 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
Study NCT01701934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 mcg, oral, once daily for 6 months
Study NCT02724904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Standard Treatment
Study NCT02724904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Standard Treatment
Study NCT02724904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV Bolus
Study NCT03733171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLATELET RICH PLASMA
Description: PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Study NCT01701934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill daily, for 6 months
Study NCT02078388 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Study NCT04306536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortifit®
Description: Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
Study NCT00347386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Zinc (zinc sulphate)
Description: Dissolvable tablet 10 mg. Once daily during the illness
Study NCT00347386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, once daily
Study NCT02258763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Oral antibiotic for 10 days
Study NCT02258763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Oral antibiotic for 10 days
Study NCT02258763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
Study NCT02552121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (HuMax-TF-ADC)
Study NCT05532891 — intervention group
Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
Study NCT01649986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacologic intervention
Description: Diet and physical exercise
Study NCT01649986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceuticals (Armolipid Plus)
Description: Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
Study NCT01019850 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vorinostat
Description: Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
Study NCT01555307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical range of motion and muscle strengthening exercises, and balance exercises
Description: Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
Study NCT01555307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Typical group
Description: Seven typical exercises, 10 times each, 3 times a day
Study NCT00237809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine (30 mg/kg)
Study NCT00237809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Retraining (CRT)
Description: Cognitive retraining therapy (CRT)
Study NCT00237809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo D-serine Drug
Study NCT01019850 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 131- I Metaiodobenzylguanidine
Description: Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
Study NCT01019850 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral Blood Stem Cell Infusion
Description: Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
Study NCT01019850 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
Study NCT01673204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: dosage of 0.5mcg administered orally once daily for 12 month
Study NCT00592332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
Study NCT00592332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
Study NCT00372697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate 30 mg suspension
Description: Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
Study NCT02787915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC1-CTL
Description: Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
Study NCT01549873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol adjusted to maintain the bispectral index at 40-60.
Study NCT01549873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane adjusted to maintain the bispectral index at 40-60.
Study NCT00946907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
Study NCT00946907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
Study NCT03247127 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Hippocampal avoidance whole brain radiotherapy
Description: Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
Study NCT01841255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthpiece (Umox)
Description: Device used to perform preoxygenation in the operating room context
Study NCT01841255 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: facemask
Study NCT01939366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 100 µg
Description: Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
Study NCT01939366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 300 µg
Description: Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.